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ABSTRACT 
 
Background: Multiple sclerosis (MS) is a T cell mediated autoimmune disease with 
unknown etiology. Appropriate MS therapeutic strategies need thorough understanding 
of both disease etiology and pathogenesis mechanisms. Ligation of TLR-2 and TLR-4 
stimulates the production of several cytokines leading to CNS autoimmunity and 
neurodegenerative diseases. Objective: To find a relationship between MS disability 
and TLR-2 and TLR-4 expression on mononuclear cells in the blood of MS patients. 
Methods: Forty-five new case (NC) MS patients (33 females and 12 males) and 45 age 
and gender-matched healthy controls (HC) were recruited to the study. PBMCs were 
prepared and the expressions of TLR-2 and TLR-4 were assessed by flowcytometry 
technique using appropriate monoclonal antibodies. Results: Our results showed that 
the expression of TLR-2 and TLR-4 proteins in the patients group was significantly 
higher than that of healthy controls. TLR-2 but not TLR-4 was correlated with expanded 
disability status scale (EDSS) scores. Conclusion: High expressions of TLR-2 and 
TLR-4 may represent a state of innate immune activation in patients with MS.  
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INTRODUCTION 
 
Multiple Sclerosis (MS), a chronic inflammatory demyelinating disease of the central 
nervous system, is the major cause of neurological disability which mostly affects 
young adults (1). There are four forms of the disease the most common form of which is  
Relapsing-Remitting Multiple Sclerosis (RRMS), presenting with neurological 
dysfunction followed by phases of stabilization or partial to absolute  healing. The next 
form is Secondary Progressive Multiple Sclerosis (SPMS), which expand in patients 
that already present with RRMS, is recognized by the severity of disability. The third 
form is Primary Progressive Multiple Sclerosis (PPMS), in which the first (primary) 
symptoms and disability progressively worsen over the time after illness inception. The 
last form is Progressive-relapsing MS (PRMS) which is progressive from the begining, 
with intermittent flare-ups of worsening symptoms without periods of remission (2). 
The Expanded Disability Status Scale (EDSS) is a method for measuring disability in 
MS and monitoring changes in the intensity of disability over time. The numeric range 
of EDSS is between 0-10 (3).  
It is broadly believed that MS is an autoimmune disease (4-6). There are three important 
pieces of evidence supporting that MS is an autoimmune disease. First, specific T cells 
against myelin antigen can be isolated from peripheral blood mononuclear cells 
(PBMC) of individuals with the disease (7). Second evidence supports the existence of 
altered peptide ligands (APL) in humans which have partial agonistic or antagonistic 
properties in interaction with autoreactive T cells. The next evidence is Experimental 
Autoimmune Encephalomyelitis (EAE), a demyelinating disease that mimics MS in 
many aspects and expands neurological signs and symptoms in animal models (8).  
In addition to the above mentioned features, similarity of MS with other autoimmune 
diseases, association with HLA genes (4), associations with other autoimmune disorders 
(9), and the presence of autoreactive B and T lymphocytes increase in the CNS provide 
more support to the autoimmune basis of MS (10), and can be a basis for therapeutic 
effects of corticosteroids (13) and efficacy of  plasmapheresis (12).  
Maturation of antigen presenting cells (APCs) expression of Toll-like receptors (TLR) 
(13) and activation of T cells and B cells via surface or intracellular receptors play 
important roles in the activity of the immune system. It is shown that immune cells such 
as monocytes, dendritic cells (DCs), B lymphocytes, T helper and T cytotoxic cells 
migrate to the CNS and mediate myelin destruction, axon damage, neuroinflammation 
and neurodegeneration (14,15). Both resident and infiltrated immune cells of the CNS 
express TLRs and expression of some types of TLR molecules increases in MS. The 
elevated TLR expression in the CNS may play a role in the pathogenesis of the disease 
(16,17). 
TLRs mediate responses to self components such as ssRNA, dsRNA, CpG-DNA, high 
mobility group box 1 (HMGB1), HSP70, HSP90 and Pathogen Associated Molecular 
Patterns (PAMPs). TLR-ligand binding can trigger innate immune responses such as  
inflammation, initiate leukocyte migration and also prime adaptive immune responses 
(18-20) against particular microbial agents through molecular mimicry to self antigens 
and cross-reactivity. These processes are know to have the potential in triggering 
autoimmune process (21). 
Ligation of TLR-2 and TLR-4 stimulates the production of IL-1, IL-6 and IL-12. These 
cytokines induce the differentiation of naive T cells into Th1 and Th17 lymphocytes. 
Th17 and Th1 lymphocytes produce IL-17 and IFN-γ, respectively. IL-17/IFN-γ-
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producing lymphocytes ease leukocyte migration across the blood-brain barrier and play 
a role in CNS damage. In addition, IL-1 and IL-6 suppress the differentiation of induced 
regulatory T cells (iTregs). Tregs are a main source of IL-10, the cytokine which plays 
an important role in inhibiting CNS autoimmunity (22). Ligation of TLR-2 or TLR-4 on 
myeloid dendritic cells (DCs) can also stimulate the production of IL-23, that promotes 
the production of IL-17A by CD4 T cells (23). TLR-4 ligation also supports the 
production of IL-12 p70. This cytokine induces IFN-γ production, which induces 
cellular immunity (24). It is therefore logical to assume that TLR-2 and TLR-4 ligation 
are able to contribute in CNS autoimmunity. 
The aim of present study was to investigate the relation between neuronal injury with 
TLR-2 and TLR-4 expression of mononuclear cells in the blood of patients with MS. 
 
 
MATERIALS AND METHODS  
 
This study was approved by the Ethical Committee on Human Research, Shahre Kord 
University of Medical Sciences. The volunteers were refferred to MS Clinic of Kashani 
University Hospital in Isfahan, Iran by clinician. The participants were informed about 
the procedures in the study and those who were willing to participate, donated blood 
samples and signed the informed consent.  
 
 
Table 1. Comparison of demographic characteristics and TLRs expression in MS 
patients and healthy controls. 
 
 
Groups 
P Value 
MS 
(n=45) Control 
(n=45) 
RRMS (n=39) PPMS (n=1) SPMS (n=5) 
Age (year) 26.56 ± 13.58 17 48.2 ± 5.76 33.28 ± 9.92 0.45 
Gender 
(Male/Female) 
10/29 0/1 2/3 12/33 0.75 
TLR-2  11 (3.9-16.1)  3.6 (2.3-7.9) 0.002 
TLR-4  14.5 (6.2-20.5)  2.2 (1.0-3.8) <0.0001 
● Data are Mean±SD, Median (IQR) and N (%) 
●P Values derived from t-test, Chi-square and Mann-Whitney 
 
 
Study Groups. Fourthly-five new cases (NC) of MS [33 females and 12 males, and 45 
age and gender-matched healthy control (HC) individuals were recruited into the study. 
Characteristics of patients including type of MS and EDSS scores were evaluated by an 
experienced neurologist. Accordingly, 39 patients were categorized as RRMS, 1 PPMS 
and 5 SPMS.  
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All blood samples were collected before each drug administration. Patients were 
clinically stable with an age ranging between 17-58 years (mean 32.2 ± 10.6) years 
diagnosed with MS according to the McDonald diagnostic criteria with EDSS between 
0-3 (Table 1) (25). 
Isolation and Evaluation of Peripheral Blood Mononuclear Cells E. Ten milliliters 
of venous blood was obtained from each subject. PBMCs were isolated using Ficoll-
Hypaque density gradient (Lymphodex, Germany). PBMCs were washed three times 
with Phosphate Buffer Solution (PBS) and the pellet was suspended in a solution 
composed of 92% fetal calf serum (Sigma, Germany) plus 8% DMSO (Sigma, 
Germany) and stored in liquid nitrogen. Before use, the cells were rapidly thawed, 
washed and resuspended in 4 ml of RPMI 1640 medium (Gibco, Germany). The cell 
number was estimated using light microscopy and the viability of the cells was checked 
by trypan blue (0.4%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Representative Forward Scatter/Side Scatter (FSC/SCC) plot of PBMC by flow 
cytometry in patient (A) and control sample (C). Flow cytometric histograms of TLR2 expression 
on PBMC in MS patient (B) and healthy control (D). (Isotype control: M1, TLR2-Positive cells: 
M2). 
 
 
 
Flowcytometry for Expression of TLR-2 and TLR-4. To determine the TLR-2 and 
TLR-4 surface expression, PBMCs were stained using the following monoclonal 
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antibodies: FITC-conjugated TLR-2 (ab13553, Abcam, UK) and FITC-conjugated 
antibodies TLR-4 (ab45126, Abcam, UK) and monoclonal antibody (IgG) FITC (Dako, 
X0932, USA) as an isotype control according to the manufacturer’s instructions. 
Briefly, 100 µl of the cells were incubated with 2 µl of anti-TLR antibodies and isotype 
control for 30 min at 4ºC. Then the cells were washed twice and resuspended in 500 µl 
PBS, containing 0.5% formaldehyde. Samples were analyzed using BD FACS Calibur 
flow cytometer using BD Cell Quest software (Figures 1 and 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Representative Forward Scatter/Side Scatter (FSC/SCC) plot of PBMC by flow 
cytometry in patient (A) and control sample(C). Flow cytometric histograms of TLR4 expression 
on PBMC in MS patient (B) and healthy control (D). (Isotype control: M1, TLR4-Positive cells: 
M2). 
 
 
 
Statistical Analysis. The data presented as Mean ± SD and Median (25th and 75th 
percentile) for continuous variables and number (percent) for categorical ones. Because 
the number of patients in each group was smaller than 50, we used the Shapiro-Wilk test 
for normality. Statistical differences among studied groups were assessed by 
Independent Samples t-test, Mann-Whitney, Pearson Chi-square and Pearson correlation 
test. All analyses were done using Statistical Package for Social Sciences version 20 
(SPSS Inc., Chicago, IL, USA) and P-values less than 0.05 were considered statistically 
significant.  
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RESULTS 
 
Ninety participants (66 men and 24 women) entered to the study. The ages ranged from 
17 to 58 years, with a mean age of 32.15 ± 10.69 years and a median age of 32 years. 
Other demographic and clinical features of the study population are shown in detail in 
Table 1. As shown in Table 1, the age and sex structure of the studied groups is well 
distributed (p>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. TLR-2 expression on PBMCs from MS patients and healthy controls. The columns of 
graphs showed the total results, and values were expressed as Mean Fluorescence Intensity 
(MFI). The expression of TLR-2 on PBMCs was significantly higher in new case patients 
compared to the healthy controls (p=0.0004). 
 
 
TLR-2 and TLR-4 expression on Mononuclear Cells Surface. The expression of 
TLR-2 on the surface of mononuclear cells in new case MS patients and healthy donors 
was quantified using flowcytometry analysis. Cell surface expression of TLR-2 in new 
case patients and healthy donors was 11.79 ± 5.70 and 5.18 ± 3.73, respectively, which 
was significantly different (p=0.0004). Mean fluorescence Intensity (MFI) of TLR-2 in 
new case patients was also significantly higher than healthy donors (p=0.0004, Figure 
3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. TLR-4 expression on PBMCs from MS patients and healthy controls. The columns of 
graphs showed the total results, and values were expressed as Mean Fluorescence Intensity 
(MFI). The expression TLR-4 on PBMCs were significantly higher in new case patients group 
compared to the healthy controls (p=0.0001). 
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TLR-4 cell surface expression was also analyzed using flowcytometry. Cell surface 
expression of TLR-4 in new case patients and healthy donors was 14.09 ± 7.35 and 3.88 
± 1, respectively, which was significantly different (p=0.0001). The Mean fluorescence 
Intensity (MFI) of TLR-4 in new case patients was also significantly higher than healthy 
donors (p=0.0001, Figure 4). 
Correlation of TLR-2 but not TLR-4 with EDSS Score. As shown in Figure 5, a 
statistically significant correlation was found between TLR-2 levels and EDSS scores 
(p=0.049, r=0.168). However, there was no significant correlation between TLR-4 
levels and EDSS scores (p=0.58, r=0.09). 
Figure 5. Correlation between TLR-2 and TLR-4 expression on PBMC and EDSS score in MS 
patients. A significant correlation between TLR2 and EDSS score is apparent (A). There is no 
significant correlation between TLR-4 and EDSS score (B).(Pearson correlation test). 
 
 
 
DISCUSSION 
 
The most suggested hypothesis about pathogenesis of MS disease and its 
phatophysiology is the autoimmune mechanism. Both innate and adaptive immunity are 
likely to take part in MS pathogenesis. It is now known that the innate immune 
responses, through the production of proinflammatory cytokines and also through 
antigen presentation play a very important role in the activation of myelin-specific 
autoreactive T cells. Therefore, the innate and adaptive immune systems cooperate in 
MS and EAE pathogenesis. It is believed that Monocytes/Macrophages and Th1/Th17 
cell subsets contribute in this process (26). These cells express TLRs and recognize 
PAMPs on the surface of pathogens. Following PAMPs binding to TLRs, innate 
immune cells produce proinflammatory cytokines and act as APCs to prime naive T 
cells for recognizing antigens (27). 
Our study showed that TLR-2 and TLR-4 on PBMCs correlate with MS 
neurodegeneration. We have identified TLR-2 and TLR-4 overexpression on PBMC of 
MS patients in comparison with healthy controls. Bystander activation and molecular 
mimicry are the suggested mechanisms for triggering autoimmune responses in the CNS 
by pathogenes, which are likely to be mediated by TLRs. Tissue damage can unmask 
myelin antigens, resulting in epitope spread and expansion of autoimmunity (28-29). 
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TLR-2 is a ligand for Gram-positive bacteria such as Staphylococcus aureus and 
Streptococcus pneumoniae. Cell wall of these bacteria contains molecules such as 
peptidoglycan (PGN), which act as PAMPs and can activate TLR-2. Some viral 
molecules can also activate immune system via TLR-2 or TLR-4 as seen in Herpes 
simplex virus 1 (30). 
Our study shows the relation between expression of TLR-2, TLR-4, and neuronal 
damage in the CNS in NC patients with MS.  
There is evidence showing the active role of TLR-2 in EAE pathogenesis. S. aureus 
PGN added to Incomplete Freund's Adjuvant (IFA) stimulates EAE development in 
C57BL/6 mice (13). Another study showed that there is an association between PGN 
and APCs in the CNS of MS patients as well as in non-human primates (31). These 
studies suggest that PGN and may be the other TLR agonists can access the CNS during 
EAE, which might ease the reactivation of myelin-reactive T cells in the CNS tissue 
during EAE and MS and pathogenesis proces. These studies also showed that the effects 
of S. pneumoniae on EAE were TLR-2 dependent, because animals with TLR-2 
deficiency could not develop more severe EAE (15). 
LPS is the only well known ligand for TLR-4. Other exogenous or endogenous TLR 
ligands may be important in pathogenesis of MS. TLR-4 can trigger signaling, both 
MyD88-dependent pathway and MyD88-independent pathways that can explain the 
somewhat paradoxical results of the effects of TLR-4 agonists in modulating EAE. 
Ligand binding to TLR-2 and TLR4 induces the production of cytokines such as IL-1, 
IL-6 and IL-12, which induce the differentiation of naive T lymphocytes into Th1 and 
Th17 cells. Th17 and Th1 cells produce IL-17 and IFN-γ. These cells ease leukocyte 
movement across the blood-brain barrier and can also attack CNS tissue (32-35).  
In the present study the levels of TLR-2 and TLR-4 expression were measured to 
explore the possible relation between TLR-2 and TLR-4 expressions with autoimmune 
mechanism of neurodegeneration in MS disease. Our results showed that there are TLR-
2 and TLR-4 overexpressions on PBMCs of patients with MS in comparison with 
healthy controls. The significant correlation of TLR-2 expression with EDSS suggested 
that this molecule is involved in pathological pathway of MS disabilities but the similar 
correlation was not found for TLR-4.  
Therefore, TLR molecules may be used as the new targets for treatment of MS and may 
be introduced as MS screening biomarkers in suspicious and high risk groups such as 
relatives of patients for more investigations, disease activity monitoring, estimation of 
treatment effects and prognosis prediction. However, further studies are needed to 
support these claims. 
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